Serious adverse events · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawal due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in clinical relapse compared with 5‐aminosalicylic acid (low certainty).
1 finding from 1 review
Endoscopic relapse · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes endoscopic relapse compared with 5‐aminosalicylic acid (very low certainty).
1 finding from 1 review
Failure to maintain remission · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in failure to maintain clinical remission compared with placebo (moderate certainty).
2 findings from 1 review
Adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Failure to maintain clinical response · people with moderate to severe Crohn's disease in remission
Ustekinumab probably leads to lower failure to maintain clinical response compared with placebo (moderate certainty).
2 findings from 1 review
Adverse events · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Failure to maintain remission · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in failure to maintain clinical remission compared with placebo (low certainty).
1 finding from 1 review
Failure to maintain clinical response · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in failure to maintain clinical response compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
OutcomesAnalysis 1.4 · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Failure to achieve clinical remission · Patients with active Crohn's disease
The intervention leads to lower failure to achieve clinical remission (high certainty).
1 finding from 1 review
Intervention not reported
Failure to achieve clinical response (70‐point response) · Patients with active Crohn's disease
The intervention leads to lower failure to achieve clinical response (70‐point response) (high certainty).
1 finding from 1 review
Intervention not reported
Failure to achieve clinical response (100‐point response) · Patients with active Crohn's disease
The intervention leads to lower failure to achieve clinical response (100‐point response) (high certainty).
1 finding from 1 review
Intervention not reported
Endoscopic response · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in adverse events (moderate certainty).
1 finding from 1 review